

Serbian Biochemical Society

President: Marija Gavrović-Jankulović

Vice-president: Suzana Jovanović-Šanta

General Secretary: Isidora Protić-Rosić

Treasurer: Milica Popović

Scientific Board

Marija Gavrović-
Jankulović
Svetlana Dinić
Ario de Marco
Suzana Jovanović-
Šanta
Mario Gabričević
Vladimir Mihailović
Theodore G.
Sotiroudis

Natalija Polović
Andreja Rajković
Nataša Simin
Edvard Petri
Sanja Krstić
Željko Popović
Snežana Pantović
Milan Nikolić
Simeon Minić

Organization Committee

Ivan Spasojević
Tanja Ćirković
Veličković
Milica Popović
Aleksandra
Uskoković
Tijana Ćulafić
Isidora Protić-Rosić
Jovana Trbojević-Ivić
Milena Dimitrijević
Srđan Miletić

Proceedings

Editor: Ivan Spasojević

Technical support: Jovana Trbojević-Ivić, Milena Dimitrijević, Tijana Ćulafić

Cover design: Zoran Beloševac

Publisher: Faculty of Chemistry, Serbian Biochemical Society

Printed by: Colorgrafx, Belgrade

No of printed copies: 130

Serbian Biochemical Society
Twelfth Conference

International scientific meeting

September 21-23, 2023, Belgrade, Serbia

“Biochemistry in Biotechnology”

Anticancer potential of diiron thiocarbonyne complexes

Ekatarina Mihajlović^{1*}, Sanja Jelača¹, Lorenzo Biancalana², Lorenzo Chiaverini²
Biljana Dojčinović³, Sanja Mijatović¹, Stefano Zacchini⁴, Fabio Marchetti², Danijela
Maksimović-Ivanić¹

¹*Department of Immunology, Institute for Biological Research “Siniša Stanković” – National Institute of Republic of Serbia, University of Belgrade, Serbia*

²*Department of Chemistry and Industrial Chemistry, University of Pisa, Italy*

³*Institute of Chemistry, Technology and Metallurgy – Institute of National Importance for the Republic of Serbia, University of Belgrade*

⁴*Department of Industrial Chemistry “Toso Montanari”, University of Bologna, Italy*

* e-mail: ekatarina.mihajlovic@ibiss.bg.ac.rs

To improve safety and efficacy of conventional chemotherapeutics, it is important to target cancer cells more selectively. Potential strategies could arise from differences in iron metabolism between healthy and cancer cells, based on cancer cells high demands for iron. Their, so-called, “iron addiction” sets a foundation for new therapeutic approach. In this study, the cytotoxic effect of three diiron carbonyl complexes with a bridging thiocarbonyne ligand was evaluated on different human cancer cell lines (HCT116 colorectal carcinoma, MCF-7 breast cancer and A2780 ovarian cancer), as well as on human embryonic lung fibroblasts (MRC-5), which were used for selectivity assessment. The most potent compound (FETPY) decreased viability of all cancer cell lines in dose-dependent manner, while A2780 cells emerged as the most sensitive. Therefore, they were selected for further investigation. On the other hand, the effect of FETPY on lung fibroblasts viability was remarkably less potent, showing its great selectivity towards malignant phenotype. Additionally, it was shown that intracellular iron concentration was much higher in A2780 than in MRC-5 cells after treatment with FETPY. Viability decrease of A2780 cells was a consequence of cell death – ferroptosis, caused by iron-dependent lipid peroxidation and membrane damage. Oxidative stress that caused ferroptosis evolved from intensive production of nitric oxide and superoxide anion. Controversially, it was followed with scavenging of hydrogen peroxide and peroxyxynitrite. Treatment with FETPY also caused significant decrease of A2780 cells division rate. Overall, these results indicate that the considered diiron derivatives show great potential for further investigation in cancer treatment.

Acknowledgements

This study was supported by the Ministry of Science, Technological Development and Innovation of the Republic of Serbia (Grant No. 451-03-47/2023-01/200007).